Aurli_150841_GZG
(Plasmid
#162563)
-
PurposeInactivation of Aurli_150841 (crtIBY) in Aurantiochytrium limacinum MYA-1381 with zeocin resistance driven by native GAPDH promoter/termiator system.
-
Depositing Lab
-
Sequence Information
Ordering
Item | Catalog # | Description | Quantity | Price (USD) | |
---|---|---|---|---|---|
Plasmid | 162563 | Standard format: Plasmid sent in bacteria as agar stab | 1 | $85 |
Backbone
-
Vector backbonepUC19
-
Backbone manufacturerNew England Biolabs
- Backbone size w/o insert (bp) 2686
- Total vector size (bp) 9190
-
Modifications to backboneAlso added two 2 kb arms of homology from Aurli_150841 (one upstream and one downstream) of the zeocin construct (GZG).
-
Vector typeUnspecified
-
Selectable markersZeocin
Growth in Bacteria
-
Bacterial Resistance(s)Ampicillin, 100 μg/mL
-
Growth Temperature37°C
-
Growth Strain(s)DH5alpha
-
Copy numberHigh Copy
Gene/Insert
-
Gene/Insert nameshble
-
Alt nameBleoR
-
SpeciesStreptoalloteichus hindustanus
-
Insert Size (bp)375
-
GenBank IDX52869.1 EF032505.1
- Promoter GAPDH
Cloning Information
- Cloning method Gibson Cloning
- 5′ sequencing primer M13
- 3′ sequencing primer M13 (Common Sequencing Primers)
Terms and Licenses
-
Academic/Nonprofit Terms
-
Industry Terms
- Not Available to Industry
Trademarks:
- Zeocin® is an InvivoGen trademark.
Depositor Comments
Plasmid was constructed using Infusion Cloning (Clontech/ Takara)
These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.
-
For your Materials & Methods section:
Aurli_150841_GZG was a gift from Jackie Collier (Addgene plasmid # 162563 ; http://n2t.net/addgene:162563 ; RRID:Addgene_162563) -
For your References section:
Horizontal Gene Transfer and Fusion Spread Carotenogenesis Among Diverse Heterotrophic Protists. Rius M, Rest JS, Filloramo GV, Novak Vanclova AMG, Archibald JM, Collier JL. Genome Biol Evol. 2023 Mar 3;15(3):evad029. doi: 10.1093/gbe/evad029. 10.1093/gbe/evad029 PubMed 36805209